# A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

> **NCT06055166** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Chongqing University Cancer Hospital** · enrollment: 120 (estimated)

## Conditions studied

- PARP Inhibitor for Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm))

## Key facts

- **NCT ID:** NCT06055166
- **Lead sponsor:** Chongqing University Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2024-11-30
- **Final completion:** 2026-05-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2023-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06055166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06055166, "A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06055166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*